6.03MMarket Cap-0.18P/E (TTM)
1.2200High1.1100Low794.11KVolume1.2100Open1.2500Pre Close1.00MTurnover14.96%Turnover RatioLossP/E (Static)5.43MShares15.060052wk High1.61P/B5.89MFloat Cap1.060052wk Low--Dividend TTM5.31MShs Float5032.5000Historical High--Div YieldTTM8.80%Amplitude1.0600Historical Low1.2650Avg Price1Lot Size
Alzamend Neuro Stock Forum
Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs
Thursday, 12th December at 8:00 am
• During the six months ended October 31, 2024, net cash provided by financing activities was $8.3 million
• Stockholder equity of $3.8 million at October 31, 2024, including $4.1 million of cash
• Strengthened balance sheet in preparation for five clinical trials to be initiated in 2025
Alzamend Neuro, Inc. (NASDAQ: ALZN) ("...
Alzamend Neuro Tells Benzinga 'Identified Dose Is Unlikely to Require Lithium Therapeutic Drug Monitoring'
Benzinga· just
On Wednesday, Alzamend Neuro, Inc. (NASDAQ:ALZN) said it received the final full data set from its multiple ascending dose clinical trial for AL001 for dementia related to Alzheimer's. Preliminary results were released in June 2023.
Identified by an independent safety review committee, this MTD represents a pivotal ...
Larger Image: tradingview.com...
$Alzamend Neuro (ALZN.US)$
No comment yet